GenoSafe
GenoSafe is a French contract research organization founded in 2003 that provides GLP/GMP/GCP-compliant analytical services for Advanced Therapy Medicinal Products, including gene therapies, cell therapies, and RNA-based products, serving pharma, biotech, CMO/CDMO, and academic clients across 15+ countries.
- Company typePrivate
- Founded2003
- HeadquartersÉvry, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What GenoSafe does
GenoSafe is a France-based contract research organization (CRO) founded in 2003 and headquartered on the Genopole campus in Évry-Courcouronnes, specializing exclusively in the analytical characterization of Advanced Therapy Medicinal Products (ATMPs), including AAV and lentiviral gene therapies, cell therapies (including CAR-T), innovative vaccines, and DNA/RNA-based therapeutics. The company operates three service lines spanning the development lifecycle: preclinical development (biodistribution, immunogenicity, biomarker detection), quality control (method qualification and GMP-compliant batch release testing), and clinical development (immunogenicity monitoring and clinical sample analysis). Method development and validation are performed under an integrated GLP/GMP/GCP quality system, with GLP certification held continuously since 2008 from the French agency ANSM and methods validated per ICH guidelines; BSL3 laboratories support lentiviral vector testing.
The firm's technology stack is centered on molecular biology and immunoassay platforms (qPCR/RTqPCR/dPCR, ELISA, MSD-ECLA, flow cytometry, spectrophotometry) and a high-throughput automated nucleic acid extraction capability spanning more than 90 tissue and fluid types. GenoSafe maintains 90 validated analytical methods, adds roughly 15 new validated tests per year, analyzes approximately 750 drug samples annually, and has supported 40+ preclinical studies and nearly 50 clinical studies across 35 indications since 2015. The company participates in European pre-competitive initiatives including the ARDAT standardization consortium and the UshTher gene therapy project, and has a study director roster of Ph.D.-level scientists recruited from Genethon, Institut Pasteur, INSERM, CEA, and Pharnext.
GenoSafe generates revenue through professional services contracts with pharmaceutical companies, biotechnology companies, CMO/CDMOs, and academic institutions across more than 15 countries. All work is delivered through direct sales led by a Head of Business Development, with dedicated study managers assigned to each project; pricing is project-based and not publicly disclosed. The company is privately held as a French simplified joint stock company (SAS) with €650,000 share capital, no disclosed institutional investors or funding rounds, and a recent leadership refresh including CEO Alain Lamproye (February 2025, ex-Yposkesi/SK pharmteco) and a new Quality Director and CFO. In November 2025 the firm inaugurated a new 1,200 m² GMP-compliant quality control laboratory that will expand commercial-stage testing capacity when fully operational in 2026.
GenoSafe firmographics
Firmographics- Name
- GenoSafe
- Legal name
- GenoSafe
- Website
- https://genosafe.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GenoSafe is a French contract research organization founded in 2003 that provides GLP/GMP/GCP-compliant analytical services for Advanced Therapy Medicinal Products, including gene therapies, cell therapies, and RNA-based products, serving pharma, biotech, CMO/CDMO, and academic clients across 15+ countries.
- Ownership category
- akta.pro rank
GenoSafe industry classification
Industry- Product category
- Contract Research Organization (Analytical Services for ATMPs)
- NAICS
- Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
- akta.pro secondary industries
- Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
Keywords
Where GenoSafe is headquartered
LocationHeadquarters
- HQ city
- Évry
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
GenoSafe business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services (CRO): GenoSafe generates revenue through providing analytical contract research services to pharmaceutical, biotech companies, CMO/CDMOs, and academic institutions. Services cover method development, validation, and sample analysis across preclinical, quality control, and clinical phases for advanced therapy medicinal products.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
GenoSafe product offering
Product offeringCore offering
GenoSafe is a French contract research organization providing analytical services for the characterization and evaluation of advanced therapy medicinal products (ATMPs), including gene therapies (AAV, lentiviral), cell therapies, innovative vaccines, and DNA/RNA-based therapeutics. Services span method development, validation, and sample analysis across preclinical, quality control, and clinical phases, delivered through GLP/GMP/GCP-compliant laboratories. Each project is supported by a dedicated study manager.
Product overview
GenoSafe is a French CRO (Contract Research Organization) specializing in the characterization and evaluation of innovative therapeutics, offering analytical services throughout drug development phases. The company operates three core service areas: Preclinical Development, Quality Control, and Clinical Development. Preclinical Development encompasses biodistribution analysis, immunogenicity assessment, and biomarker detection. Quality Control focuses on GMP-compliant testing for Advanced Therapy Medicinal Products (ATMPs) including AAV gene therapy, lentivirus gene therapy, and cell therapy testing. Clinical Development supports patient immunogenicity monitoring through neutralizing antibody titration and clinical sample analysis. Services are delivered across specialized platforms including PCR (qPCR/RTqPCR/dPCR), ELISA, MSD-ECLA, flow cytometry, and Spectrophotometry, with GLP certification since 2008 and GMP compliance for quality control operations.
Differentiator
Problem solved
Functional benefit
Products and services
- Preclinical Development Services
Quantifiable outcome
- 40+ preclinical studies completed
- +5 more outcomes
Companies that use GenoSafe
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
GenoSafe technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
GenoSafe partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- ARDAT (Accelerating Research & Development for Advanced Therapies)coreGenoSafe is one of the major players in this international consortium of experts and leaders in innovative therapeutics. The consortium aims to develop and provide necessary tools and data to strengthen knowledge on gene and cell therapies. GenoSafe contributes to standardization and harmonization of detection and titration methods used in gene therapies.
- UshTher ProjectcoreEuropean collaborative project evaluating safety and efficacy of innovative gene therapy approach for retinis pigmentosa (USH1B) in humans. GenoSafe contributed to biodistribution/biodissemination studies and immunogenicity studies for the gene therapy candidate.
Scale indicators13 records
Recent moves7 records
Expansion highlights5 records
GenoSafe competitors and assessment
Company assessmentEmerging players
- CellGenix: German-headquartered supplier of cell and gene therapy raw materials (cytokines, growth factors, media) with growing QC and analytical service offerings. Adjacent to GenoSafe's ATMP-focused services with partial overlap in cell therapy characterization.
Broad incumbents
- Charles River Laboratories: Large US-headquartered CRO with established cell and gene therapy testing services spanning safety, biodistribution, and QC. Comparable to GenoSafe in that it offers analytical services for ATMPs, but operates at vastly greater scale and breadth across multiple therapeutic modalities.
- Eurofins Scientific: Global testing-services group with pharma-services and cell/gene therapy testing operations. Overlaps with GenoSafe's analytical testing scope for ATMPs but offers a vastly broader portfolio across pharma, food, environmental and clinical diagnostics.
- Sartorius: Bioprocessing and cell therapy solutions provider including QC and analytics offerings through its bioprocess and BPS segments. Comparable in offering analytical tools for advanced therapy production but a much larger incumbent operating across upstream/downstream bioprocessing.
- PPD (Thermo Fisher Scientific): Thermo Fisher-owned global CRO offering clinical development and bioanalytical services including cell and gene therapy programs. Comparable to GenoSafe's clinical development arm in serving ATMP clinical trials, but at vastly larger scale and global infrastructure.
- IQVIA: World's largest CRO with biotech/pharma-focused analytical, clinical, and laboratory services. Overlaps with GenoSafe's clinical sample analysis and immunogenicity work for advanced therapies but offers far broader capabilities and global reach.
Direct peers
- Novasep: French-headquartered CDMO with biopharma and gene therapy services, including the previously gene-therapy-focused Henogen subsidiary sold to Thermo Fisher. Overlaps with GenoSafe's ATMP analytical service offering and shares operational Paris-region presence.
- Yposkesi: French gene therapy CDMO providing process development, manufacturing, and analytical services for AAV and lentiviral vectors. Highly comparable to GenoSafe's ATMP-focused analytical offerings and notably employs GenoSafe's new CEO Alain Lamproye's previous leadership.
- Cobra Biologics (Charles River): CDMO specializing in viral vector and plasmid DNA manufacturing and analytical services for gene therapy and vaccine developers, now part of Charles River. Directly comparable to GenoSafe's lentiviral and AAV QC testing and serves the same advanced therapy client base.
- Vectalys: French CRO/CDMO specializing in lentiviral vector design, production, and analytical services. Directly comparable to GenoSafe's lentiviral-focused testing capabilities (infectious titer, RCL, VCN) and serves the same biotech and academic client base.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
GenoSafe social profiles
Digital presenceGenoSafe compliance and trust
Trust signalCompliance4 records
GenoSafe financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenoSafe leadership team
Management profileNumber of profiles
Profiles12 records
GenoSafe funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenoSafe M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenoSafe
What does GenoSafe do?
GenoSafe is a French contract research organization providing analytical services for the characterization and evaluation of advanced therapy medicinal products (ATMPs), including gene therapies (AAV, lentiviral), cell therapies, innovative vaccines, and DNA/RNA-based therapeutics. Services span method development, validation, and sample analysis across preclinical, quality control, and clinical phases, delivered through GLP/GMP/GCP-compliant laboratories. Each project is supported by a dedicated study manager.
Is GenoSafe a public or private company?
GenoSafe is a private company. It is classified as unknown and is currently operating.
When was GenoSafe founded?
GenoSafe was founded in 2003. It employs 11 to 50 people.
Where is GenoSafe based?
GenoSafe is headquartered in Évry, France, in the Europe region.
How does GenoSafe make money?
One revenue line is on record: contract Research Services (CRO).
Who are GenoSafe's main competitors?
CellGenix is listed as an emerging player. Broad incumbents are Charles River Laboratories, Eurofins Scientific, Sartorius, PPD (Thermo Fisher Scientific) and IQVIA. Direct peers are Novasep, Yposkesi, Cobra Biologics (Charles River) and Vectalys.
Does GenoSafe have an API?
No public API is recorded for GenoSafe.
What industry is GenoSafe in?
GenoSafe's product category is Contract Research Organization (Analytical Services for ATMPs). Its primary akta.pro industry code is HLAGAEAD, Genomics & Molecular Diagnostics (Trial Support), with a secondary code of HLAAACAM, Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services. Its NAICS code is 621511 and its SIC code is 8731.